ClinicalTrials.gg
Enrolling by invitationNCT07382063Updated Feb 3, 2026

Effects of Extra-fascial Interscalene Brachial Plexus Block on Diaphragmatic Function in School-Aged Children

An interventional study of extra-fascial interscalene brachial plexus block (ISB) and intra-fascial interscalene brachial plexus block (ISB) in Diaphragm Movement, sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital. Enrolling by invitation at 1 site in China. Open to participants aged 6 Years to 12 Years. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Shanghai Jiao Tong University Affiliated Sixth People's Hospital · Not applicable, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
72
Allocation
Randomized
Ages
6 Years to 12 Years
Sex
All
01

Study summary

The traditional intra-fascial interscalene brachial plexus block (ISB) is already one of the routine anesthesia methods for pediatric upper limb surgeries in clinical practice. This study aims to clarify the effect of the extra-fascial interscalene brachial plexus block on the diaphragm function of school-age children, as well as its analgesic effect, and to compare it with the traditional intra-fascial ISB. It intends to explore a more effective and safer ISB method for children. With the aim of optimizing techniques and accurately evaluating, to balance the benefits of analgesia and safety, and thereby promoting the development of precise pediatric anesthesia.

02

Conditions studied

  • Diaphragm Movement
03

In context

Lead sponsor

Shanghai Jiao Tong University Affiliated Sixth People's Hospital is the lead sponsor of 41 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
6 Years to 12 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age range: School-aged children (6-12 years old).
  • Type of surgery: Upper limb surgery.
  • : Grades I-II.

Exclusion criteria

Exclusion Criteria:

  • Infection, anatomical deformity, or tumor at the puncture site.
  • Coagulation disorders ( > 1.4, count \< 100 × 10⁹/L).
  • History of allergy to local anesthetics (ropivacaine).
  • Severe cardiopulmonary or neurological diseases (e.g., epilepsy, myopathy).
  • Pre-existing ipsilateral phrenic nerve paralysis or Horner syndrome.
  • Preoperative long-term use of analgesics (which may affect efficacy assessment).
  • Parent or child refusal to participate in the study.
  • Emergency surgery or inability to cooperate with assessments (e.g., severe developmental delay).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
72 participants (estimated)

Study arms

  • Placebo comparator
    intra-fascial interscalene brachial plexus block (ISB)

    Procedure: intra-fascial interscalene brachial plexus block (ISB)

  • Experimental
    extra-fascial interscalene brachial plexus block (ISB)

    Procedure: extra-fascial interscalene brachial plexus block (ISB)

Interventions

  • Procedureextra-fascial interscalene brachial plexus block (ISB)

    Perform an extra-fascial interscalene brachial plexus block, positioning the needle tip 2-4 mm lateral to the brachial plexus sheath, at a level equidistant between the C5 and C6 roots, measured using the on-screen caliper tool. Inject 0.5 ml/kg of 0.2% ropivacaine for nerve blockade.

  • Procedureintra-fascial interscalene brachial plexus block (ISB)

    Perform an intra-fascial interscalene brachial plexus block by penetrating the brachial plexus fascia and injecting 0.5 ml/kg of 0.2% ropivacaine.

06

What researchers measure

Primary outcomes

  1. To evaluate the rate of diaphragmatic paralysis using ultrasound.

    Time frame: From enrollment to the end of treatment at 2-3 days

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Feb 2026; primary completion for Oct 2026, 8 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 26, 2026
First posted
Feb 2, 2026
StartEst.
Feb 1, 2026
Primary completionEst.
Oct 31, 2026
CompletionEst.
Nov 30, 2026
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07382063
Lead sponsor
Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Responsible party
Jiaqi Shan (anesthesiologist, Shanghai Jiao Tong University Affiliated Sixth People's Hospital) — Principal investigator
First posted
Feb 2, 2026
Start date
Feb 1, 2026 (estimated)
Primary completion
Oct 31, 2026 (estimated)
Completion
Nov 30, 2026 (estimated)
Last update
Feb 3, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion